Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Published:2011-05 Issue: Volume: Page:303
ISSN:1176-6328
Container-title:Neuropsychiatric Disease and Treatment
language:en
Short-container-title:NDT

Author:

Berman Robert,Berman Robert,Thase Michael,Trivedi Madhukar,Hazel ,Marler ,McQuade ,Carson ,Baker Ross,marcus ronald

Publisher

Informa UK Limited

Subject

Biological Psychiatry,Psychiatry and Mental health

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of aripiprazole discontinuation in remitted major depressive disorder: a randomized placebo-controlled trial;Psychopharmacology;2024-03-28

2. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis;Medicine;2023-09-22

3. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression;New England Journal of Medicine;2023-05-25

4. Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis;Life;2023-04-19

5. Recent advances in dopamine D ₂ receptor ligands in the treatment of neuropsychiatric disorders;Medicinal Research Reviews;2022-09-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP